Author: Rodrigo Arrangoiz MS, MD, FACS, FSSO

• Complement System:
  • The complement cascade is a system of immune proteins:
    • That activates in a cascade-like fashion:
      • To fight infection and promote tissue repair:
        • But also contributes to inflammation and disease when overactivated
  • It works via three pathways (classic, lectin, alternative):
    • That converge to create inflammatory fragments called:
      • Anaphylatoxins and form a membrane attack complex (MAC) that can kill pathogens
  • Beyond infection:
    • Complement plays roles in clearing cellular debris, facilitating tissue regeneration, and regulating neuronal function:
      • But inappropriate activation can cause:
        • Chronic pain, autoimmune disease, and organ damage
  • Pathways and Triggers:
    • Each pathway initiates the cascade through different triggers but ultimately leads to the same outcomes: 
      • Classical Pathway: 
        • Activated by the binding of antibodies (like IgG and IgM) to antigens:
          • On the surface of a pathogen
      • Lectin Pathway: 
        • Initiated when mannose-binding lectin (MBL):
          • Binds to carbohydrate structures on bacterial cell walls 
      • Alternative Pathway: 
        • Triggered by the direct binding of complement components to foreign surfaces, such as pathogens, without the need for antibodies 
    • Classical pathway (antibody-dependent):
      • Trigger: 
        • C1q, a component of the C1 protein complex:
          • Binds to an antibody-antigen complex:
            • On a pathogen surface
          • The C1 complex is composed of:
            • C1q, C1r, and C1s
      • Cascade:
        • C1r and C1s are activated:
          • Which then cleave complement proteins C4 and C2
          • The larger fragments, C4b and C2b (also called C2a):
            • Bind together to form the classical pathway’s C3 convertase (C4b2b) 
      • Antigen – antibody complexes:
        • Best: 
          • IgM:
            • Then IgG1 / IgG3
      • Early components unique to this pathway: 
        • C1 (C1q, C1r, C1s), C2, C4
      • C1 protein complex:
        • Needs Ca²⁺:
          • To stay assembled
    • Lectin pathway (antibody-independent; same cascade as classical after C4):
      • Trigger: 
        • The pattern recognition molecule:
          • Mannose-binding lectin (MBL) or ficolins:
            • Bind to specific carbohydrate patterns (like mannose) on the surface of pathogens
      • Cascade:
        • This binding activates MBL-associated serine proteases (MASPs):
          • Which are functionally similar to C1r and C1s
        • The MASPs cleave C4 and C2:
          • Forming the same C3 convertase (C4b2b) used by the classical pathway 
      • Mannose-binding lectin (MBL) or ficolins binding microbial sugars:
        • Enzymes: 
          • MASP-1 / MASP-2 cleave C4 and C2:
            • Merges with classic pathway a:
              • C3 convertase (C4b2a)
    • Alternative pathway (antibody-independent; tickover on surfaces):
      • Trigger: 
        • This pathway is always active at a low level through a “tickover” mechanism:
          • Where C3 is spontaneously hydrolyzed
        • It is further activated when C3b, a fragment of C3:
          • Binds directly to the surface of a pathogen or foreign material
      • Cascade:
        • Factor B binds to the surface-bound C3b and is then cleaved by Factor D to form C3bBb:
          • The alternative pathway’s C3 convertase
        • The protein properdin stabilizes this complex:
          • Amplifying the cascade
        • This pathway also acts as an amplification loop for the classical and lectin pathways
      • Spontaneous C3 hydrolysis on microbial / endotoxin surfaces:
        • Amplified by Factor B, Factor D, Properdin (P)
        • Note: 
          • Mg²⁺ is required for Factor B binding to C3b
          • Properdin stabilizes the convertase
      • Common note: 
        • C3:
          • Common to and is the convergence point for the three pathways
    • The final, common pathway:
      • All three initiation pathways converge to form a C3 convertase:
        • Which ultimately leads to the creation of the:
          • Membrane attack complex (MAC) 
      • C3 cleavage:
        • A C3 convertase cleaves C3 into two pieces:
          • C3a:
            • A small fragment that acts as a potent:
              • Anaphylatoxin, triggering inflammation
          • C3b:
            • A larger fragment that acts as an opsonin, or “tag,” marking the pathogen for destruction
            • It also attaches to the C3 convertase to create a C5 convertase
      • C5 cleavage:
        • The C5 convertase cleaves C5 into C5a (a potent anaphylatoxin and chemoattractant) and C5b
      • Membrane Attack Complex (MAC):
        • The C5b fragment recruits and assembles the remaining complement proteins (C6, C7, C8, and multiple C9 molecules):
          • To form a cylindrical pore in the pathogen’s membrane:
            • This pore disrupts the cell’s osmotic balance:
              • Causing it to lyse and die
    • C3 / C5 Convertases (know these cold):
      • Classical / Lectin pathway:
        • C3 convertase: 
          • C4b2a
        • C5 convertase: 
          • C4b2a3b
      • Alternative pathway:
        • C3 convertase: 
          • C3bBb:
            • Stabilized by Properdin / P
        • C5 convertase: 
          • C3bBb3b
      • Effector Functions (the “what does each piece do?”):
        • Anaphylatoxins: 
          • C3a, C4a, C5a:
            • ↑ vascular permeability
            • Vasodilation
            • Bronchoconstriction
            • Mast cell / basophil degranulation
          • Potency: 
            • C5a > C3a >> C4a (C4a is weak)
        • Chemotaxis (especially neutrophils): 
          • C5a is the major chemoattractant:
            • C3a contributes mainly as anaphylatoxin
          • C5a drives:
            • Leukocyte recruitment
            • Adhesion up-regulation
            • Oxidative burst
        • Opsonization: 
          • C3b (and iC3b), C4b
          • Coat pathogens (marks them for destruction):
            • CR1 / CR3 on phagocytes bind → enhanced phagocytosis
        • Membrane Attack Complex (MAC): 
          • C5b to C9
          • C5b:
            • Nucleates assembly with C6, C7, C8, C9 (polymerizes) → pore → osmotic lysis (classically Neisseria)
      • Ion Requirements (exam-friendly correction):
        • Classical and Lectin Pathway: 
          • Ca²⁺ required for C1qrs (classical) and MBL – MASP (lectin) complexes:
            • Mg²⁺ also involved downstream
        • Alternative pathway: 
          • Mg²⁺ essential for Factor B – C3b interaction and convertase formation:
            • So: not “Mg for both pathways”:
              • Only – Classical / Lectin need Ca²⁺
              • Alternative needs Mg²⁺ (and Properdin)
      • Regulation (why we don’t self-destruct):
        • C1 inhibitor (C1-INH): 
          • Blocks C1r / C1s and MASPs 1/2 (MASP-1 / MASP-2 cleave C4 and C2):
            • Turns off classic / lectin pathways early
        • Factor H and Factor I: 
          • Inactivate C3b (→ iC3b) on host cells:
            • Factor H prefers sialic acid – rich self surfaces
        • DAF / CD55: 
          • Disrupts C3 / C5 convertases on host cells
        • CD59 (Protectin): 
          • Blocks C9 polymerization:
            • Prevents MAC on self cells
        • Clinical Correlates (high-yield):
          • C1-INH deficiency → Hereditary angioedema:
            • Bradykinin-mediated edema:
              • ACE inhibitors worsen
            • Treat with C1-INH concentrate, bradykinin pathway blockers
          • C2 deficiency (most common classic pathway deficiency):
            • SLE-like disease, recurrent sinopulmonary infections
          • C3 deficiency:
            • Recurrent severe pyogenic infections:
              • Especially encapsulated bacteria; immune complex disease.
          • Terminal complement (C5 to C9) deficiency:
            • Recurrent Neisseria (meningitidis, gonorrhoeae)
          • DAF / CD55 or CD59 deficiency (e.g., PNH via PIGA mutation):
            • Intravascular hemolysis, hemoglobinuria, thrombosis
            • Treat with C5 inhibitors:
              • Eculizumab / ravulizumab
          • Factor H / I abnormalities:
            • Atypical HUS, C3 glomerulopathy
        • Laboratory Assessment:
          • CH50:
            • Total classic pathway function:
              • Low in classic component defects or terminal pathway defects
          • AH50:
            • Total alternative pathway function
          • Heat-labile:
            • Complement activity falls if serum is mishandled / warmed
      • Quick “Apply It” Pearls:
        • Suspected meningococcemia with recurrence:
          • Check terminal complement (C5 to C9)
        • Recurrent pyogenic infections with low C3:
          • Evaluate classic / alternative convertase regulation
        • Episodic angioedema without urticaria:
          • Think C1-INH deficiency
        • Autoimmunity in a young patient + low early classic components (C1q/C2/C4) → screen for complement deficiencies
      • One-Page Memory Map:
        • Triggers:
          • Classic pathway: 
            • IgM / IgG immune complexes → C1qrs (Ca²⁺)
          • Lectin pathway: 
            • MBL / ficolin (MASPs) → C4, C2
          • Alternative pathway: 
            • C3 tackover + B, D, Properdin (Mg²⁺)
          • Convertases:
            • Classic / Lectin: 
              • C4b2a (C3), C4b2a3b (C5)
            • Alternative:
              • C3bBb (C3), C3bBb3b (C5)
          • Effectors:
            • Opsonins: 
              • C3b/iC3b (± C4b)
            • Anaphylatoxins: 
              • C5a > C3a >> C4a
            • Chemotaxis: 
              • C5a
            • MAC: C5b to C9
          • Regulators: 
            • C1-INH, Factor H / I, DAF (CD55), CD59
          • Deficiencies (buzzwords): 
            • C1-INH—HAE
            • C2—SLE-like
            • C3—pyogenic infections
            • C5–C9—Neisseria
            • DAF/CD59—PNH
            • Factor H/I—aHUS
              
              

• Hepatic acute-phase response (APR) in trauma — what rises, what falls, and why it matters
  • What it is?
    • Within hours of significant injury:
      • IL-6 (with TNF-α / IL-1) shifts hepatocyte transcription toward acute-phase proteins (APPs):
        • Away from constitutive proteins
      • This fuels host defense:
        • Opsonization, complement, coagulation control, metal sequestration:
          • But distorts common labs

• Procalcitonin (PCT):
  • Rises after major trauma but is not hepatic:
    • It’s produced systemically (notably in bacterial sepsis):
      • Helpful to distinguish sterile inflammation vs secondary infection (trajectory matters)

How this maps onto trauma phases

• Ebb (0 to 24 hours): 
  • Catecholamines / cortisol surge
  • TNF-α / IL-1 spark response
  • IL-6 begins hepatic switch
• Flow – catabolic (days 1–7): 
  • CRP / SAA peak
  • Fibrinogen, complement, haptoglobin, hepcidin rise
  • Albumin / transferrin / prealbumin fall
  • Plasminogen Activator Inhibitor-1 (PAI-1):
    • Favors impaired fibrinolysis
• Flow – anabolic (weeks): 
  • APR tapers
  • APPs normalize as repair predominates:
    • IL-10 / TGF-β tone higher

High-yield clinical pearls for surgery/ICU

• CRP trend > single value:
  • Expect a 48 to 72 hour peak post-op:
    • A secondary rise suggests infection / collection
• Hepcidin / ferritin pattern:
  • Low iron, low transferrin, high ferritin = anemia of inflammation:
    • Avoid reflex iron unless functional deficiency is proven
• Coagulation:
  • ↑ fibrinogen and PAI-1 tilt toward thrombosis:
    • Combine with VTE prophylaxis early unless contraindicated
• Drug dosing:
  • ↓ albumin raises free acidic drugs (e.g., phenytoin)
  • ↑ α-1-acid glycoprotein (AGP) / orosomucoid lowers free basic drugs (e.g., lidocaine)
  • Monitor levels / clinical effect
• Nutrition metrics:
  • Albumin / prealbumin reflect inflammation, not intake:
    • Use calorie / protein delivery, nitrogen balance, indirect calorimetry or functional metrics instead

Selected references

• Gabay C, Kushner I. Acute-phase proteins and systemic response to inflammation. N Engl J Med. 1999.
• Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003.
• Heinrich PC, et al. Interleukin-6-type cytokine signaling in hepatocytes. Biochem J. 2003.
• Castell JV, Andus T. IL-6 and the acute-phase response. Biochem J. 1991/1992.
• Ganz T, Nemeth E. Hepcidin and iron homeostasis in inflammation. Nat Rev Immunol. 2015.
• Marnell L, Mold C, Du Clos TW. CRP and host defense. Immunol Res. 2005.
• Meisner M. Procalcitonin—biochemistry and clinical diagnosis. 2010 (monograph).

• Ebb phase:
  • First 6 to 24 hours to 48 hours:
    • “Shock, conserve”
  • Characterize by:
    • Hypometabolism
    • ↓O₂ consumption
    • Relative hypothermia
    • Neuroendocrine surge:
      • Catecholamines
      • Cortisol
      • Glucagon
    • The innate immune system is triggered:
      • Early TNF-α / IL-1 release:
        • Begins the inflammatory cascade / response PMC+1
• Flow phase:
  • Catabolic sub-phase:
    • From days ~ 1 to 7:
      • “Hypermetabolism, mobilize”
  • Characterize by:
    • ↑O₂ consumption
    • Hyperglycemia
    • Insulin resistance
    • Proteolysis
    • TNF-α and IL-1 drive the early wave:
      • Rapidly followed by IL-6:
        • Acute-phase switch
      • IL-8:
        • Neutrophil recruitment (PMN chemotaxis)
        • Angiogenesis
      • Counter-regulators like IL-10:
        • To prevent runaway inflammation
    • Clinically corresponds to SIRS:
      • An anti-inflammatory counter-swing (CARS):
        • Follows and may blend into MARS in severe injury PubMed+1
• Flow phase:
  • Anabolic / Recovery sub-phase:
    • Last weeks
  • Characterize by:
    • Gradual resolution of catabolism:
      • As inflammation recedes and tissue repair predominates
    • Cytokine tone shifts toward regulation and remodeling:
      • Persistent but lower IL-6:
        • More IL-10 / TGF-β signals ScienceDirect

• Conceptual arc: 
  • TNF-α / IL-1 ignite the response → IL-6 flips on the acute-phase program → IL-8 pulls in neutrophils (and supports angiogenesis) → IL-10 tempers the fire
  • In severe trauma, this oscillates between SIRS → CARS (sometimes MARS), tracking clinical risk for infection or organ failurePubMed+1
• Practical pearls you can teach on rounds:
  • CRP is an IL-6 barometer:
    • Rising CRP tracks the IL-6–driven hepatic response more than bacterial growth per se PubMed
  • Fever mechanics: 
    • IL-1 / TNF → PGE₂ in the hypothalamus:
      • Antipyretics reduce PGE₂ synthesis (COX inhibition) PMC
  • Atelectasis ≠ fever:
    • The long-taught notion that postoperative atelectasis causes fever isn’t supported by clinical data:
      • Early fevers are cytokine-mediated inflammation from surgical injury unless another source is found PubMed+1
• Summary (link cytokines to phases):
  • Ebb (0 to 24 hours ): 
    • Catecholamines / cortisol ↑
    • TNF-α / IL-1 spark local and systemic inflammation PMC
  • Flow:
    • Catabolic (days 1 to 7): 
      • IL-6 → CRP / SAA
      • IL-8 → neutrophil recruitment / angiogenesis
      • Persistent SIRS risks early MOF
      • Rising IL-10 signals CARS BioMed Central+1
    • Flow:
      • Anabolic (weeks): 
        • Inflammation resolves
        • IL-10 / TGF-β tone dominates
        • Net protein balance turns positive with rehab / nutrition ScienceDirect
• References:
  • Ebb/flow framework: Cuthbertson/Wilmore lineage and modern updates. PMC+1
  • TNF-α endothelial activation/adhesion: Parameswaran & Patial. PMC
  • IL-1 → PGE₂ fever (EP3 in POA): Blomqvist et al. PMC
  • IL-6 drives CRP/SAA (human hepatocytes): Castell et al.; Sack et al. PubMed+1
  • IL-8 neutrophil chemotaxis/angiogenesis: Cambier et al.; Koch et al. Nature+1
  • IL-10 anti-inflammatory: Schulte et al. PMC
  • SIRS → CARS model after trauma: Lenz et al.; Bone RC. PubMed+1
  • Atelectasis–fever myth: Mavros et al.; Stein et al. 

• Leukotrienes:
  • Are a family of potent inflammatory lipid mediators:
    • Derived from arachidonic acid in white blood cells (leukocytes) and other immune cells
  • Produced rapidly in response to injury, infection, or allergens
  • Leukotrienes:
    • Act as local hormones:
      • That help regulate immune and inflammatory responses 
• Biosynthesis pathway:
  • Leukotrienes are produced through the 5-lipoxygenase (5-LO) pathway 
  • An increase in intracellular calcium:
    • Activates the enzyme phospholipase A2 (cPLA2):
      • Which releases arachidonic acid (AA) from cell membrane phospholipids
  • AA is converted into an unstable epoxide intermediate:
    • Leukotriene A4 (LTA4):
      • Through a two-step process catalyzed by the 5-lipoxygenase enzyme.
    • LTA4 then branches into two main pathways:
      • Leading to the formation of two distinct classes of leukotrienes:
        • LTB4:
          • An LTA4 hydrolase enzyme converts LTA4 into leukotriene B4 (LTB4):
            • LTB4 is primarily involved in recruiting neutrophils and other leukocytes to inflammatory sites
        • Cysteinyl leukotrienes:
          • A separate enzyme, LTC4 synthase, conjugates LTA4 with glutathione to create:
            • Leukotriene C4 (LTC4):
              • LTC4 is subsequently metabolized into leukotriene D4 (LTD4) and leukotriene E4 (LTE4) by other enzymes
• Functions of leukotrienes :
  • Leukotrienes exert their effects by binding to G-protein-coupled receptors (GPCRs) on the surface of target cells 
  • LTB4:
    • Acts as a potent chemoattractant:
      • Recruiting immune cells like neutrophils, eosinophils, and T-cells to inflamed tissues
      • It is also involved in the initial sensitization phase of allergic responses
  • Cysteinyl Leukotrienes (CysLTs): The CysLTs (LTC4, LTD4, and LTE4) cause:
    • Bronchoconstriction
    • Increased vascular permeability:
      • Leading to swelling (edema) and the leakage of plasma and immune cells into tissues
    • Mucus production:
      • Stimulating the release of excess mucus, particularly in the airways
• Role in inflammatory diseases:
  • Because of their role in promoting inflammation:
    • Leukotrienes are implicated in a number of chronic inflammatory and allergic diseases
  • Asthma:
    • Overproduction of CysLTs is a major cause of the airway inflammation and bronchoconstriction seen in asthma, particularly exercise-induced asthma and aspirin-sensitive asthma
  • Allergic rhinitis:
    • CysLTs contribute to nasal congestion, mucus production, and other symptoms associated with hay fever
  • Rheumatoid arthritis and inflammatory bowel disease:
    • The pro-inflammatory effects of leukotrienes have been linked to these and other conditions
  • Cardiovascular disease:
    • Recent research suggests leukotrienes also play a role in cardiovascular diseases like atherosclerosis
• Clinical applications:
  • The central role of leukotrienes in inflammation makes them a target for medications called leukotriene modifiers
  • 5-Lipoxygenase inhibitors:
    • Drugs like zileuton block the 5-LO enzyme, preventing the synthesis of all leukotrienes (LTB4 and CysLTs)
  • Leukotriene receptor antagonists (LTRAs):
    • Drugs like montelukast (Singulair) and zafirlukast (Accolate) block CysLTs from binding to their receptors
    • These are primarily used to manage asthma and allergic rhinitis. 
  • By interfering with the leukotriene pathway:
    • These drugs can help manage symptoms associated with inflammatory and allergic conditions

• Post-op intermediate-risk pathology:
  • Perineural Invasion (PNI)
  • Lymphovascular Invasion (LVI)
  • pT3
  • ENE-negative
  • Negative margins
• Standard adjuvant plan: 
  • Postoperative radiation therapy (RT) alone (no concurrent cisplatin)
• Why?:
  • Two landmark randomized trials established who benefits from adding cisplatin to adjuvant RT:
    • EORTC 22931 (Bernier, NEJM 2004):
      • Showed CRT > RT overall in a broad high-risk cohort:
        • Improving PFS / OS:
          • Its Kaplan–Meier curves separate for combined therapy New England Journal of Medicine+2PubMed+2
    • RTOG 9501 (Cooper, NEJM 2004; 10-yr update 2012):
      • In the entire randomized population:
        • CRT did not significantly improve OS / DFS vs RT alone:
          • The KM benefit emerges only in the pre-specified subgroup with:
            • Positive margins and / or extranodal extension (ENE+):
              • Better LRC and DFS; OS trend
          • Outside that subgroup:
            • Curves do not show a clear advantage for adding cisplatin New England Journal of Medicine+2PubMed+2
    • Comparative analysis of EORTC 22931 and RTOG 9501 (Bernier et al., Head & Neck 2005):
      • Concluded the most consistent benefit from adjuvant CRT is confined to:
        • ENE+ and / or positive margins
      • Features such as pT3, PNI, LVI, or multiple nodes without ENE:
        • Did not reproducibly show survival benefit from adding cisplatin PubMed+1
• Guideline take-home:
  • Contemporary guidelines reflect these data:
    • For intermediate-risk pathology (PNI / LVI, pT3, multiple nodes without ENE, clear margins):
      • RT alone is recommended:;
        • Concurrent cisplatin is reserved for ENE+ and / or positive (or non-re-resectable “close”) margins JNCCN
  • Site-specific guidance (ASTRO 2024 HPV+ OPSCC):
    • Likewise recommends post-op RT alone for intermediate-risk categories:
      • Reserving systemic therapy for ENE+ or positive margins ScienceDirect+2ASTRO+2
• Practical pearls:
  • Don’t over-treat intermediate-risk patients with cisplatin unless risk escalators exist (e.g., ENE+, positive / non-re-resectable close margin):
    • This avoids unnecessary nephrotoxicity / ototoxicity / neurotoxicity without proven survival gain:
      • KM patterns from RTOG 9501:
        • Show separation only in ENE + / R + PubMed
  • RT planning: 
    • Typical adjuvant doses 60 to 66 Gy to the primary bed / high-risk nodal regions with elective coverage as indicated by subsite and pathologic mapping (per institutional / NCCN frameworks) JNCCN
  • Clinical trials:
    • If available, consider enrollment for intermediate-risk biology:
      • Biomarkers, de-intensification / intensification questions
      • Observational work underscores prognostic value of PNI / LVI but does not establish a chemotherapy benefit post-operatively PMC+1
• Bottom line: 
  • For PNI / LVI / pT3 (ENE-negative, margins clear):
    • Post-operative RT alone is the guideline-concordant standard.
  • Reserve cisplatin-RT for:
    • ENE+ and / or positive / irremediably close margins:
      • Which is where randomized trials (and their Kaplan–Meier curves):
        • Show the benefit of adding chemotherapy

• Design:
  • Phase III, randomized, non-inferiority trial: 
    • Micrometastatic (≤ 2 mm) SLN, tumor ≤ 5 cm, clinically node-negative (cN0); no extracapsular extension
  • Randomized:
    • ALND vs no ALND
  • Primary endpoint: 
    • DFS:
    • NI margin HR 1.25
  • Population:
    • N = 934 randomized:
      • ALND 465
      • No-ALND 469
    • Median age ≈ 55
    • Most patietns had:
      • Breast-conserving surgery (~ 91%)
      • Tumors < 3 cm (~ 92%)
      • Received adjuvant systemic therapy (~ 96%)
      • Mastectomy (~ 9%)
  • 5-year results (primary publication, Lancet Oncology 2013):
    • 5-yr DFS: 
      • 87.8% (No-ALND) vs 84.4% (ALND):
        • HR 0.78 (95% CI 0.55–1.11):
          • Non-inferior (p for NI = 0.0042)
    • Axillary / regional recurrences (early report): 
      • Very low and similar:
        • Reported counts: 
          • 1 ALND vs 5 No-ALND over early follow-up -absolute numbers small
    • Toxicity: 
      • Grade 3 to 4 surgical morbidities (neuropathy / lymphedema) occurred almost exclusively in the ALND arm
    • Conclusion: 
      • In SLN micro metastases:
        • Omitting ALND did not compromise DFS and reduced morbidity
  • 10-year update (Lancet Oncology 2018):
    • Median follow-up 9.7 y (IQR 7.8–12.7).
    • 10-yr DFS: 
      • 76.8% (No-ALND) vs 74.9% (ALND):
        • HR 0.85 (95% CI 0.65–1.11); log-rank p = 0.24:
          • Non-inferiority maintained (p for NI = 0.0024)
    • Long-term morbidity: 
      • Lymphedema (any grade):
        • 4% No-ALND vs 13% ALND
      • Sensory neuropathy 
        • 13% No-ALND vs 19% ALND
      • Motor neuropathy:
        • 3% No-ALND vs 9% ALND
  • Interpretation: 
    • 10-year outcomes corroborate 5-year findings and align with Z0011:
      • ALND can be omitted when SLN tumor burden is minimal
  • Practice take-home:
    • In cT1 to cT2, cN0 patients with SLN micrometastases ≤ 2 mm, skip ALND: 
      • Non-inferior DFS to 10 years and meaningfully less arm morbidity
    • Fits the broader de-escalation arc alongside ACOSOG Z0011 (1 to 2 macrometastases-positive SLNs in BCT + WBRT → omit ALND) and AMAROS (if nodal control needed, axillary RT ≈ ALND with less lymphedema)

• What to do right now?
  • Stop cisplatin permanently:
    • Grade-3 renal toxicity signals significant tubular injury with risk of incomplete recovery:
      • Continuing platinum can cause irreversible damage
    • FDA labeling flags severe, cumulative nephrotoxicity and advises dose reduction or alternatives in renal impairment Cancer Treatment and Diagnosis+1
  • Continue radiation on schedule and switch the systemic partner only if the patient can tolerate it:
    • Preferred: 
      • RT + cetuximab (loading 400 mg / m² → 250 mg / m² weekly):
        • If infusion tolerance and skin toxicity risk acceptable
          • Evidence for postoperative use is not as mature as for cisplatin:
            • But RTOG 0234 showed feasibility and favorable signals with cetuximab-based regimens
          • Several groups (and guidelines) allow cetuximab when cisplatin is contraindicated
      • If not feasible, RT alone is acceptable PMC
• Supportive care (same day):
  • Nephrology consult:
    • Classify per CTCAE v5.0 and KDIGO:
      • Check urine studies,:
        • Mg / K / Ca / PO₄ ctep.cancer.gov+1
  • Aggressive IV hydration with isotonic saline and magnesium supplementation:
    • Hold other nephrotoxins:
      • NSAIDs, IV contrast, aminoglycosides
  • Routine mannitol isn’t required:
    • May be considered selectively at very high cisplatin doses:
      • Not applicable here since cisplatin is being stopped eviq.org.au
  • Frequent labs (serum Cr / eGFR, electrolytes) until recovery:
    • Document nadir eGFR for the chart
• What NOT to do?
  • Do not re-challenge with cisplatin after a grade-3 AKI in the adjuvant setting:
    • Renal injury may recover incompletely and worsen with further exposure eviq.org.au+1
  • Avoid reflex “swap to carboplatin” in the adjuvant post-op setting after severe AKI:
    • Carboplatin is renally cleared and, while less nephrotoxic, lacks adjuvant level-I evidence with RT for head and neck
    • Prior cisplatin exposure can also predispose to carboplatin – AKI
    • If considered at all:
      • Do so only with nephrology input and careful pharmacokinetics Frontiers
• Finishing the course (practical scenarios):
  • If some cisplatin already given but < 200 mg /m²: 
    • Aim to complete RT with cetuximab if the patient can tolerate it:
      • Otherwise proceed with RT alone
  • ≥ 200 mg / m² is the commonly cited efficacy threshold in CRT literature:
    • If already achieved, simply finish RT BC Cancer
  • If weekly cisplatin was planned (JCOG1008 context): 
    • That RCT supports weekly as a valid starting schedule post-op:
      • But once grade-3 AKI occurs:
        • The same rules appl:
          • Stop cisplatin and transition as above PubMed
• One-page order set:
  • Hold cisplatin permanently.
  • RT: 
    • Continue per plan
    • Coordinate new concurrent agent start within 0 to 3 days
  • Cetuximab (if chosen):
    • 400 mg / m² load → 250 mg / m² weekly through RT
      • Premedicate; dermatitis prophylaxis PMC
  • Renal bundle: 
    • NS 1 to 2 L / day IV while inpatient or symptomatic
    • MgSO₄ per lab
    • Stop ACEi/ARBs/NSAIDs/IV contrast if possible
    • Daily weights
    • I/Os eviq.org.au
  • Monitoring: 
    • BMP / Mg daily until stable:
      • Then every 48 to 72 hours
    • Re-stage eGFR at 2 to 4 weeks
    • KDIGO-based follow-up for AKI recovery KDIGO
• Bottom line: 
  • After grade-3 AKI, do not give more cisplatin
  • Finish radiation and, if feasible, add cetuximab (or proceed with RT alone) while executing a tight renal-recovery plan (hydration, magnesium, nephrotoxin avoidance, close labs)
  • This balances cure intent with kidney safety, in line with contemporary supportive-care guidance

• What was the primary objective of the SOUND trial?
  • Answer:
    • To determine whether sentinel lymph node biopsy (SLNB) can be safely omitted in women with early-stage, clinically node-negative breast cancer with negative axillary ultrasound:
      • Without compromising distant disease-free survival
• What does “SOUND” stand for in this trial?
  • Answer:
    • SOUND stands for:
      • Sentinel node vs Observation after axillary UltraSouND
• What were the eligibility criteria for patients
  • Answer:
    • Women with unifocal invasive breast cancer ≤ 2.0 cm
    • Clinically node-negative
    • Negative axillary ultrasound (AUS)
    • Undergoing breast-conserving surgery
    • No prior neoadjuvant therapy
• Describe the study design of the SOUND trial:
  • Answer:
    • Phase 3, multicenter, randomized non-inferiority trial
      • Two arms:
        • SLNB group vs. observation (no axillary surgery)
    • Primary endpoint:
      • 5-year distant disease-free survival (DDFS)
• What was the primary endpoint, and how was non-inferiority defined?
  • Answer:
    • Primary endpoint:
      • 5-year distant disease-free survival (DDFS)
    • Non-inferiority margin:
      • Upper bound of 95% CI for the hazard ratio had to be ≤ 1.50
• What were the key results of the SOUND trial
  • Answer:
    • 5-year DDFS:
      • 95.5% (observation) vs. 96.2% (SLNB)
    • Non-inferiority was demonstrated
    • No significant difference in axillary recurrence or overall survival
• What does this trial suggest about the role of SLNB in modern breast cancer management?
  • Answer:
    • SLNB may be safely omitted in carefully selected patients with low-risk, early-stage breast cancer and negative AUS:
      • Reinforcing a less invasive, de-escalated approach
• What were the secondary outcomes, and how did they compare?
  • Answer:
    • Overall survival:
      • No difference:
        • OS at 5 yr: 
          • 98.4% vs 98.2%
    • Axillary recurrence:
      • < 1.5% in both arms
    • Quality-of-life data (previous reports) favored the observation group
• What is the clinical significance of using axillary ultrasound as a triage tool?
  • Answer:
    • Axillary ultrasound helps identify patients who do not need SLNB, reducing unnecessary surgery in node-negative disease with high diagnostic accuracy
• How does the SOUND trial compare to ACOSOG Z0011 and INSEMA?
  • Answer:
    • ACOSOG Z0011:
      • Tested omission of ALND after positive SLNB
    • INSEMA:
      • Tested omission of SLNB in cN0 patients undergoing BCS + radiation
    • SOUND:
      • Focused on completely omitting axillary surgery in AUS-negative patients
• What were some exclusion criteria in the trial
  • Answer:
    • Multifocal or multicentric disease
    • Tumors > 2.0 cm
    • Mastectomy patients
    • Neoadjuvant therapy
    • Prior axillary surgery
• What were some limitations of the SOUND trial
  • Answer:
    • Limited to low-risk patients
    • Mostly postmenopausal, HR-positive / HER2-negative tumors
    • Not generalizable to mastectomy, young, or high-risk patients
• How might omission of SLNB affect decisions about adjuvant systemic therapy?
  • Answer:
    • Without nodal staging, oncologists may rely more on tumor biology, imaging, and genomic testing to guide chemotherapy decisions
• What were the main benefits of omitting SLNB noted in the trial?
  • Answer:
    • Reduced risk of lymphedema
    • Better arm mobility
    • Improved quality of life
    • Shorter operative times and fewer complications
• Based on SOUND, how would you counsel a 62-year-old woman with a 1.5 cm ER+ / HER2 negative tumor and negative axillary ultrasound?
  • Answer:
    • She is a candidate for SLNB omission:
      • I would explain that observation is safe, doesn’t affect survival, and lowers surgical risk, but the decision should involve the oncology team to ensure systemic therapy isn’t compromised

• High-risk triggers (guideline-concordant):
  • Positive margin (R+) or close margin (institutional cutoffs commonly < 1 to 5 mm)
  • Extranodal extension (ENE / ECS +) in any positive node
• Rationale:
  • These were the features driving benefit from adding concurrent cisplatin to postoperative RT in the pivotal randomized trials and follow-ups PMC+2PMC+2
• Pivotal trials:
  • EORTC 22931 (Bernier, NEJM 2004):
    • Design: 
      • Post-op RT alone (66 Gy) vs RT + cisplatin 100 mg / m² q3wk ×3
    • 5-yr outcomes (KM estimates): 
      • OS 53% vs 40%
      • PFS 47% vs 36%:
        • Both favoring CRT
      • Reported hazard ratios (RT + Cisplatin vs RT): 
        • OS HR ≈ 0.70–0.75
        • PFS HR 0.75:
          • Benefit across most high-risk features
    • Takeaway: 
      • Clear KM separation for DFS / OS with combined therapy New England Journal of Medicine+2PubMed+2
  • RTOG 9501 (Cooper, NEJM 2004; 10-yr update 2012):
    • Design: 
      • Post-op RT alone (60 Gy/6 wk) vs RT + cisplatin 100 mg / m² on days 1, 22, 43
    • Overall cohort (10-yr KM): 
      • LRF 28.8% vs 22.3% (p=0.10)
      • DFS 19.1% vs 20.1% (p=0.25)
      • OS 27.0% vs 29.1% (p=0.31)
        • No significant advantage in the unselected population
      • Key subset (pre-specified high-risk: R+ and / or ENE+):
        • LRF 33.1% (RT) vs 21.0% (CRT), p=0.02
        • DFS 12.3% vs 18.4%, p=0.05
        • OS 19.6% vs 27.1%, p=0.07 (trend)
        • KM curves:
          • Markedly diverge in this subgroup, establishing R+ / ENE+ as the clearest indication for cisplatin-RT PubMed+1
  • Cross-trial comparative / pooled insight:
    • Bernier et al., Head & Neck 2005 compared EORTC 22931 and RTOG 9501:
      • Concluded the greatest benefit from CRT accrues to patients with:
        • ENE+ and / or positive margins PubMed+1
    • Updated combined analysis (2025):
      • Again supports an OS benefit for CRT across the combined cohorts:
        • While noting competing non-cancer mortality:
          • Still, ENE and / or R+ remain the most reproducible risk features prompting CR PubMed+1
• How to apply at tumor board:
  • Offer adjuvant cisplatin-RT when any of the following are present::
    • Positive margin:
      • R1:
        • Re-resection preferred when feasible, otherwise CRT
    • Close margin:
      • Where institutional policy treats as high risk:
        • Commonly < 1 to 5 mm, site-dependent
    • ENE / ECS+ in a lymph node (any extent) PMC
    • Intermediate-risk (e.g., PNI, LVI, pT3, pN2 without ENE, multiple nodes but ENE-negative):
      • RT alone remains standard:
        • CRT generally not indicated absent R+ / ENE+ ACS Publications
  • Cisplatin fitness: 
    • If contraindicated (CrCl < 60 mL/min, grade ≥ 2 SNHL, neuropathy, poor PS):
      • Use RT alone or alternative systemic partner per site-specific guidance:
        • But the randomized survival gain post-op is with cisplatin ACS Publications
• Quick “exam-pearl” summaries:
  • EORTC 22931: 
    • KM curves separate for PFS / OS:
      • CRT beats RT in high-risk patients overall New England Journal of Medicine
  • RTOG 9501 (10-yr): 
    • Whole cohort:
      • No OS benefit
      • R+ / ENE+ subset: 
        • Better LRC and DFS, OS trend with CRT:
          • This is the clinical trigger PubMed
    • Define “close” carefully:
      • Many centers treat < 5 mm (some < 3 mm or < 1 mm by subsite) as high-risk when re-resection isn’t possible PMC+1
• Bottom line:
  • After resection of LA-HNSCC:
    • Adjuvant cisplatin-RT is indicated for ENE+ and positive (or institutionally “close”) margin:
      • The exact groups where the Kaplan–Meier curves in RTOG 9501 and EORTC 22931 show the clearest advantage for adding chemotherapy to RT

• Sentinel lymph node biopsy (SLNB):
  • Has replaced axillary lymph node dissection (ALND) as the primary method of axillary staging for patients with early stage breast cancer, based on data from:
  • NSABP B-32 (Phase III RCT) — SLNB vs ALND in cN0 patients:
    • No differences in overall survival, disease-free survival, or regional control:
      • Markedly less morbidity with SLNB
    • Conclusion:
      • If the sentinel node is negative, SLNB alone is appropriate and safe
  • Milan / IEO Randomized Trial (Veronesi et al., NEJM 2003) — SLNB with ALND only if SLN positive vs routine ALND:
    • SLNB was safe and accurate, reducing need for complete dissection without compromising outcomes
  • ALMANAC RCT (UK) — SLNB vs standard axillary treatment:
    • Similar cancer control with significantly lower arm morbidity and better quality of life after SLNB:
      • Tecommended as treatment of choice for early cN0 disease
  • Foundational validation work that enabled the shift to SLNB:
    • Krag et al., NEJM 1998 (Multicenter validation):
      • Demonstrated reliable identification of the sentinel node and accuracy of the technique
    • Giuliano et al., Ann Surg 1994 (Feasibility / accuracy):
      • First clinical series showing lymphatic mapping and SLN biopsy accurately stage the axilla
• Changes in patient presentation and advancements in systemic therapy:
  • Have led clinicians to question the utility of ALND even in the presence of involved nodes
• The American College of Surgeons Oncology Group (ACOSOG) Z0011 trial:
  • Randomized women with cT1 / cT2 tumors undergoing breast conservation with one or two positive sentinel nodes:
    • To undergo ALND vs. no additional axillary surgery
  • Results showed no difference in local recurrence, disease-free survival (DFS), or overall survival (OS) between the groups
    • The authors concluded that ALND was not indicated in this setting
• One of the major advantages of SLNB compared to ALND:
  • Is the ability to stage the axilla with reduced rates of lymphedema
• A meta-analysis of five randomized controlled trials (including the Z0011 trial):
  • Reported a 70% reduction in risk of lymphedema with SLNB compared to ALND
• Multi-gene assays:
  • Such as the 21-gene recurrence score (RS):
    • Have provided prognostic information regarding risk of distant recurrence for patients with:
      • Node-negative, ER+ breast cancers
    • Although evidence suggests that adding chemotherapy to endocrine therapy does result in improved DFS and OS for node-positive patients:
      • Exploratory data suggest that this may not be true for all patients:
        • A retrospective analysis of the RS performed on 367 specimens from the SWOG 8814 trial:
          • Showed that RS was prognostic for DFS and OS in node-positive patients
      • The National Comprehensive Cancer Network allows patients with 1 to 3 positive nodes to consider the 21-gene recurrence score to determine benefit from chemotherapy
• References
  • Giuliano AE, Ballman K, McCall L, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg. 2016; 264(3):413-420.
  • Glechner A, Wockel A, Gartlehner G, et al. Sentinel lymph node dissection only versus complete axillary lymph node dissection in early invasive breast cancer: a systematic review and meta-analysis. Eur J Cancer. 2013;49(4):812-825.
  • Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, estrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.
  • Breast cancer. National Comprehensive Cancer Network. 2018. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf Accessed September 14, 2018.